Feng Chi Biotech P/E Ratio

Feng Chi Biotech's p/e ratio stands at 20.62. That is below the Healthcare sector average of 70.94. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Feng Chi Biotech sits lower the Healthcare benchmark (70.94) with a P/E ratio of 20.62. That is roughly 70.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 20.62 is attractive depends on Feng Chi Biotech's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Feng Chi Biotech's P/E ratio evolved across reporting periods, while the comparison chart places 6744.TWO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, P/E ratio is commonly used to spot outliers. Feng Chi Biotech's reading of 20.62 (sector avg 70.94) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.